title: Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents.
abstract: The aim of this study was to assess baseline levels and changes in plasma fatty acid profiles in children and adolescents with ADHD, in a placebo-controlled study with Omega 3/6 supplementation, and to compare with treatment response. Seventy-five children and adolescents aged 8-18 years with DSM-IV ADHD were randomized to 3 months of Omega 3/6 (Equazen eye q) or placebo, followed by 3 months of open phase Omega 3/6 for all. n-3, n-6, n-6/n-3 ratio, EPA and DHA in plasma were measured at baseline, 3 and 6 months. Subjects with more than 25 % reduction in ADHD symptoms were classified as responders. At baseline, no significant differences in mean fatty acid levels were seen across active/placebo groups or responder/non-responder groups. The 0-3 month changes in all parameters were significantly greater in the active group (p < 0.01). Compared to non-responders, the 6-month responders had significantly greater n-3 increase at 3 months and decrease in n-6/n-3 ratio at 3 and 6 months (p < 0.05). Omega 3/6 supplementation had a clear impact on fatty acid composition of plasma phosphatidyl choline in active versus placebo group, and the fatty acid changes appear to be associated with treatment response. The most pronounced and long-lasting changes for treatment responders compared to non-responders were in the n-6/n-3 ratio.
authors: The Gillberg Neuropsychiatry Centre at the Sahlgrenska Academy, Göteborg University, Kungsgatan, Sweden. johnson.mats@gmail.com
authors: Mats
authors: M
authors: Johnson
authors: Jan-Eric
authors: JE
authors: Månsson
authors: Sven
authors: S
authors: Ostlund
authors: Gunnar
authors: G
authors: Fransson
authors: Björn
authors: B
authors: Areskoug
authors: Kerstin
authors: K
authors: Hjalmarsson
authors: Magnus
authors: M
authors: Landgren
authors: Björn
authors: B
authors: Kadesjö
authors: Christopher
authors: C
authors: Gillberg
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000097:blood* / Q000178:diet therapy*; D002648:Child; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000378:metabolism; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000378:metabolism* / Q000627:therapeutic use; D043371:Fatty Acids, Omega-6 / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010713:Phosphatidylcholines / Q000378:metabolism; D010919:Placebos; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D013997:Time Factors
chemical_list: D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D010713:Phosphatidylcholines; D010919:Placebos; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid